Abstract
Cardiovascular diseases (CVDs) are the leading cause of death globally, with heart failure (HF) as a significant contributor. Biomarkers, particularly natriuretic peptides like BNP and NT-proBNP, have transformed HF diagnosis and management by offering vital insights into cardiac function and helping to distinguish cardiac from non-cardiac symptoms. Neprilysin inhibitors, such as Sacubitril/Valsartan, enhance the effects of these peptides by preventing their degradation, representing a novel therapeutic approach. This paper examines the impact of natriuretic peptides and neprilysin inhibition on HF management, highlighting their role in improving patient outcomes.